MACROGENICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
MACROGENICS, INC. (MGNX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $2.02 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-09
- MACROGENICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $2.02M, a 63.82% decline from fiscal 2024.
- MACROGENICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $5.59M, a 186.87% increase from fiscal 2023.
- MACROGENICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $1.95M, a 21.57% increase from fiscal 2022.
- MACROGENICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $1.60M, a 48.66% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.02M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $5.59M 10-K · filed 2026-03-09 | |
| 2023-12-31 | $1.95M 10-K · filed 2026-03-09 | |
| 2022-12-31 | $1.60M 10-K · filed 2025-03-20 | |
| 2021-12-31 | $1.08M 10-K · filed 2024-03-07 | |
| 2020-12-31 | $554.00K 10-K · filed 2023-03-15 | |
| 2019-12-31 | $1.89M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $758.00K 10-K · filed 2021-02-25 | |
| 2017-12-31 | $2.07M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $2.00M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $1.10M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $756.00K 10-K · filed 2017-02-28 | |
| 2013-12-31 | $241.00K 10-K · filed 2016-02-29 | $241.47K 10-K · filed 2014-03-20 |
| 2012-12-31 | $279.00K 10-K · filed 2015-03-03 | $279.17K 10-K · filed 2014-03-20 |
| 2011-12-31 | $725.81K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |